RPTX - Repare gets ~$1.5M from Ono Pharma under research pact
- Repare Therapeutics ( NASDAQ: RPTX ) said it received ~$1.5M (¥200M) research service payment from Japan's Ono Pharmaceutical ( OTCPK:OPHLF ) ( OTCPK:OPHLY ).
- The payment was due to achievement of a research trigger, under the companies' 2019 strategic partnership agreement.
- Under the terms agreement, Repare is mainly responsible for carrying out research activities for its Pol? program, now known as RP-2119, until the first submission of an IND in the U.S. or Japan, the company added.
- "This reflects an important milestone in our RP-2119 Pol? program, as we undertake our IND-enabling studies and prepare for our previously guided initiation of clinical trials in the summer of 2023," said Repare's Chief Business Officer Kim Seth.
For further details see:
Repare gets ~$1.5M from Ono Pharma under research pact